Treatment of Moderate Aortic Regurgitation
For moderate aortic regurgitation (Stage B), medical management with observation and serial imaging is the primary approach, with surgical intervention reserved only for patients undergoing cardiac or aortic surgery for other indications 1.
Medical Management Strategy
Surveillance Without Routine Pharmacotherapy
Moderate AR is generally benign and does not require specific medical treatment in most cases 2. The focus should be on:
- Serial echocardiographic monitoring to detect progression to severe AR or left ventricular changes
- Clinical assessment for symptom development, though symptoms are rare with moderate AR alone
- Blood pressure management if hypertension is present
Vasodilator Therapy: Limited Role
While vasodilators (ACE inhibitors, ARBs) have been studied in AR, their role in moderate AR is not well-established 1, 2. Consider vasodilators only if:
- Hypertension is present - this is the primary indication 3
- Patient has contraindications to surgery but shows signs of progression
Important caveat: Vasodilators do not replace or delay surgery when indicated, and results with these agents are inconsistent 4. They should not be used routinely in normotensive patients with moderate AR.
Surgical Intervention Criteria
Class IIa Recommendation (Reasonable)
Aortic valve surgery is reasonable in patients with moderate AR who are already undergoing cardiac or aortic surgery for other indications 1. This is the only surgical scenario recommended for moderate AR.
The rationale is straightforward: if the chest is already open for another cardiac procedure (e.g., coronary artery bypass, mitral valve surgery, ascending aorta repair), addressing moderate AR concurrently is reasonable to prevent future progression, as demonstrated in recent rheumatic mitral valve surgery cohorts 5.
When NOT to Operate
Do not perform isolated aortic valve surgery for moderate AR alone - there is no indication for this in current guidelines 1. Surgery is reserved for:
- Severe AR with symptoms (Stage D)
- Severe AR with LV dysfunction (LVEF <55%, Stage C2)
- Severe AR with severe LV dilation (LVESD >50 mm or indexed >25 mm/m²)
Monitoring Protocol
Serial Imaging Requirements
Establish a surveillance schedule to detect progression:
- Baseline comprehensive echocardiography to confirm moderate severity and assess LV dimensions and function
- Annual echocardiography is reasonable for stable moderate AR
- More frequent imaging (6 months) if approaching severe criteria or if LV dimensions are increasing
Key Parameters to Track
Monitor these specific measurements:
- Regurgitant volume and fraction - progression toward severe thresholds (≥60 mL, ≥50%)
- LV end-systolic dimension - watch for enlargement toward 50 mm
- LV ejection fraction - ensure it remains >55%
- LV end-diastolic dimension - track for progressive dilation
Common Pitfalls to Avoid
Over-treating with vasodilators: These medications have inconsistent results in AR and should not be prescribed routinely without hypertension 4, 2
Premature surgical referral: Moderate AR alone does not warrant surgery - patients face unnecessary surgical risks if treated prematurely 4
Inadequate surveillance: The evolution from moderate to severe AR can be insidious 2. Missing the optimal surgical window leads to worse peri- and post-operative prognosis 4
Relying solely on symptoms: Symptoms do not correlate well with objective ventricular dysfunction in AR 2. Serial imaging is essential regardless of symptom status
Special Consideration: Concurrent Cardiac Surgery
When patients with moderate AR require surgery for other cardiac conditions, the decision to address the aortic valve should be made collaboratively with the surgical team 1. Recent data from rheumatic mitral valve surgery patients shows that concurrent AVR significantly improves aortic valve status without increasing surgical risks 5, supporting the Class IIa recommendation for this scenario.